Chromium as adjunctive treatment for type 2 diabetes

Gina J. Ryan, Nancy S. Wanko, Andrea R. Redman, Curtiss B. Cook

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

OBJECTIVE: To review the chemistry, pharmacology, efficacy, and safety of trivalent chromium in the treatment of type 2 diabetes and hyperlipidemia. DATA SOURCES: The English literature was searched from 1966 through May 2002 using MEDLINE, International Pharmaceutical Abstracts, and EMBASE. The key words included chromium, glucose, lipids, and diabetes. Pertinent references from review articles and studies were used as additional sources. DATA SYNTHESIS: Trivalent chromium is an essential nutrient and has a key role in lipid and glucose metabolism. Supplementation with chromium does not appear to reduce glucose levels in euglycemia. It may, however, have some efficacy in reducing glucose levels in hyperglycemia. The effects of chromium on lipid levels are variable. Chromium in doses <1000 μg/d appears to be safe for short-term administration. Kidney function and dermatologic changes need to be monitored. CONCLUSIONS: Chromium appears to be a safe supplement and may have a role as adjunctive therapy for treatment of type 2 diabetes. Additional large-scale, long-term, randomized, double-blind studies examining the effect of various doses and forms of chromium are needed.

Original languageEnglish (US)
Pages (from-to)876-885
Number of pages10
JournalAnnals of Pharmacotherapy
Volume37
Issue number6
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Chromium
Type 2 Diabetes Mellitus
Glucose
Literature
Lipids
Hyperlipidemias
Lipid Metabolism
Double-Blind Method
MEDLINE
Hyperglycemia
Pharmacology
Kidney
Safety
Food
Pharmaceutical Preparations

Keywords

  • Chromium
  • Diabetes
  • Glucose
  • Lipids

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ryan, G. J., Wanko, N. S., Redman, A. R., & Cook, C. B. (2003). Chromium as adjunctive treatment for type 2 diabetes. Annals of Pharmacotherapy, 37(6), 876-885. https://doi.org/10.1345/aph.1C304

Chromium as adjunctive treatment for type 2 diabetes. / Ryan, Gina J.; Wanko, Nancy S.; Redman, Andrea R.; Cook, Curtiss B.

In: Annals of Pharmacotherapy, Vol. 37, No. 6, 01.06.2003, p. 876-885.

Research output: Contribution to journalArticle

Ryan, GJ, Wanko, NS, Redman, AR & Cook, CB 2003, 'Chromium as adjunctive treatment for type 2 diabetes', Annals of Pharmacotherapy, vol. 37, no. 6, pp. 876-885. https://doi.org/10.1345/aph.1C304
Ryan, Gina J. ; Wanko, Nancy S. ; Redman, Andrea R. ; Cook, Curtiss B. / Chromium as adjunctive treatment for type 2 diabetes. In: Annals of Pharmacotherapy. 2003 ; Vol. 37, No. 6. pp. 876-885.
@article{4810f6f226d6493ba663f391d6b654b2,
title = "Chromium as adjunctive treatment for type 2 diabetes",
abstract = "OBJECTIVE: To review the chemistry, pharmacology, efficacy, and safety of trivalent chromium in the treatment of type 2 diabetes and hyperlipidemia. DATA SOURCES: The English literature was searched from 1966 through May 2002 using MEDLINE, International Pharmaceutical Abstracts, and EMBASE. The key words included chromium, glucose, lipids, and diabetes. Pertinent references from review articles and studies were used as additional sources. DATA SYNTHESIS: Trivalent chromium is an essential nutrient and has a key role in lipid and glucose metabolism. Supplementation with chromium does not appear to reduce glucose levels in euglycemia. It may, however, have some efficacy in reducing glucose levels in hyperglycemia. The effects of chromium on lipid levels are variable. Chromium in doses <1000 μg/d appears to be safe for short-term administration. Kidney function and dermatologic changes need to be monitored. CONCLUSIONS: Chromium appears to be a safe supplement and may have a role as adjunctive therapy for treatment of type 2 diabetes. Additional large-scale, long-term, randomized, double-blind studies examining the effect of various doses and forms of chromium are needed.",
keywords = "Chromium, Diabetes, Glucose, Lipids",
author = "Ryan, {Gina J.} and Wanko, {Nancy S.} and Redman, {Andrea R.} and Cook, {Curtiss B.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1345/aph.1C304",
language = "English (US)",
volume = "37",
pages = "876--885",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - Chromium as adjunctive treatment for type 2 diabetes

AU - Ryan, Gina J.

AU - Wanko, Nancy S.

AU - Redman, Andrea R.

AU - Cook, Curtiss B.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - OBJECTIVE: To review the chemistry, pharmacology, efficacy, and safety of trivalent chromium in the treatment of type 2 diabetes and hyperlipidemia. DATA SOURCES: The English literature was searched from 1966 through May 2002 using MEDLINE, International Pharmaceutical Abstracts, and EMBASE. The key words included chromium, glucose, lipids, and diabetes. Pertinent references from review articles and studies were used as additional sources. DATA SYNTHESIS: Trivalent chromium is an essential nutrient and has a key role in lipid and glucose metabolism. Supplementation with chromium does not appear to reduce glucose levels in euglycemia. It may, however, have some efficacy in reducing glucose levels in hyperglycemia. The effects of chromium on lipid levels are variable. Chromium in doses <1000 μg/d appears to be safe for short-term administration. Kidney function and dermatologic changes need to be monitored. CONCLUSIONS: Chromium appears to be a safe supplement and may have a role as adjunctive therapy for treatment of type 2 diabetes. Additional large-scale, long-term, randomized, double-blind studies examining the effect of various doses and forms of chromium are needed.

AB - OBJECTIVE: To review the chemistry, pharmacology, efficacy, and safety of trivalent chromium in the treatment of type 2 diabetes and hyperlipidemia. DATA SOURCES: The English literature was searched from 1966 through May 2002 using MEDLINE, International Pharmaceutical Abstracts, and EMBASE. The key words included chromium, glucose, lipids, and diabetes. Pertinent references from review articles and studies were used as additional sources. DATA SYNTHESIS: Trivalent chromium is an essential nutrient and has a key role in lipid and glucose metabolism. Supplementation with chromium does not appear to reduce glucose levels in euglycemia. It may, however, have some efficacy in reducing glucose levels in hyperglycemia. The effects of chromium on lipid levels are variable. Chromium in doses <1000 μg/d appears to be safe for short-term administration. Kidney function and dermatologic changes need to be monitored. CONCLUSIONS: Chromium appears to be a safe supplement and may have a role as adjunctive therapy for treatment of type 2 diabetes. Additional large-scale, long-term, randomized, double-blind studies examining the effect of various doses and forms of chromium are needed.

KW - Chromium

KW - Diabetes

KW - Glucose

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=0037809569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037809569&partnerID=8YFLogxK

U2 - 10.1345/aph.1C304

DO - 10.1345/aph.1C304

M3 - Article

C2 - 12773078

AN - SCOPUS:0037809569

VL - 37

SP - 876

EP - 885

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 6

ER -